-
公开(公告)号：IL318530A
公开(公告)日：2025-03-01
申请号：IL31853025
申请日：2025-01-21
Inventor： PERL NICHOLAS ROBERT , KUNTZ KEVIN WAYNE
Abstract: The present invention relates to quinazolinones and related compounds which degrade PARP14 and are useful, for example, in the treatment of cancer and inflammatory diseases.
-
公开(公告)号：IL318518A
公开(公告)日：2025-03-01
申请号：IL31851825
申请日：2025-01-21
Applicant: ABBVIE OPERATIONS SINGAPORE PTE LTD , PERL NICHOLAS ROBERT , KUNTZ KEVIN WAYNE , DOWNING JENNIFER
Inventor： PERL NICHOLAS ROBERT , KUNTZ KEVIN WAYNE , DOWNING JENNIFER
Abstract: The present invention relates to quinazolinones and related compounds which degrade PARP14 and are useful, for example, in the treatment of cancer and inflammatory diseases.
-
公开(公告)号：AU2015317823A1
公开(公告)日：2017-03-23
申请号：AU2015317823
申请日：2015-09-16
Applicant: BARDEN TIMOTHY CLAUDE , MERMERIAN ARA , IYENGAR RAJESH R , PERL NICHOLAS , JUNG JOON , IM G-YOON JAMIE , RENNIE GLEN ROBERT , JIA JAMES , IRONWOOD PHARMACEUTICALS INC
Inventor： RENNIE GLEN ROBERT , PERL NICHOLAS , MERMERIAN ARA , JUNG JOON , JIA JAMES , IYENGAR RAJESH R , IM G-YOON JAMIE , BARDEN TIMOTHY CLAUDE , SHEPPECK JAMES EDWARD , RENHOWE PAUL ALLAN , NAKAI TAKASHI , LEE THOMAS WAI-HO , IYER KARTHIK
IPC: C07D401/14 , A61K31/4155 , A61P9/08 , A61P37/06 , C07D401/04 , C07D405/14 , C07D413/14 , C07D417/14
Abstract: The present patent application discloses at least the compounds according to Formula I' shown below, or pharmaceutically acceptable salts thereof, Formula (I) wherein ring D, ring A, ring E, J
-
公开(公告)号：AU2015317818A1
公开(公告)日：2017-03-23
申请号：AU2015317818
申请日：2015-09-16
Applicant: PERL NICHOLAS , LEE , NAKAI TAKASHI , IRONWOOD PHARMACEUTICALS INC
Inventor： PERL NICHOLAS , NAKAI TAKASHI , LEE THOMAS WAI-HO , RENNIE GLEN ROBERT , RENHOWE PAUL ALLAN , IYENGAR RAJESH R
IPC: C07D471/04 , A61K31/4985 , A61P9/10 , C07D487/04 , C07D498/04
Abstract: The present patent application discloses at least the compounds according to Formula I' shown below, or pharmaceutically acceptable salts thereof, Formula I' wherein ring D, ring A, ring E, ring F, J
-
公开(公告)号：WO2016044445A3
公开(公告)日：2016-03-24
申请号：PCT/US2015/050464
申请日：2015-09-16
Applicant: IRONWOOD PHARMACEUTICALS, INC. , RENNIE, Glen Robert , PERL, Nicholas , LEE, Thomas Wai-Ho
Inventor： RENNIE, Glen Robert , PERL, Nicholas , LEE, Thomas Wai-Ho , RENHOWE, Paul Allan , NAKAI, Takashi , MERMERIAN, Ara , IM, G-Yoon Jamie
IPC: C07D401/14 , C07D405/14 , C07D413/14 , C07D401/04 , C07D417/14 , A61K31/4155 , A61P9/08 , A61P37/06
Abstract: The present patent application discloses at least the compounds according to Formula (Ia) and Formula (Ib) shown below, or pharmaceutically acceptable salts thereof, wherein ring D, ring A, J B , n, J, R C1 , R C2 , Z 1 , Z 2 , W, X, Y 1 , Y2, J F and R 9 are as defined herein.
-
Patent Agency Ranking
公开(公告)号：WO2014047325A1
公开(公告)日：2014-03-27
申请号：PCT/US2013/060680
申请日：2013-09-19
Applicant: IRONWOOD PHARMACEUTICALS, INC. , NAKAI, Takashi , PERL, Nicholas, Robert , MOORE, Joel
Inventor： NAKAI, Takashi , PERL, Nicholas, Robert , MOORE, Joel
IPC: C07D413/14 , A61K31/506 , A61P7/00 , A61P9/00 , A61P15/00
CPC classification number: A61K31/513 , A61K31/4155 , A61K31/506 , A61K31/519 , A61K31/5377 , A61K45/06 , C07D403/04 , C07D413/14 , C07D487/04 , A61K2300/00
Abstract: The present patent application discloses at least the compounds according to Formula I or Formula lb shown below, or pharmaceutically acceptable salts thereof, wherein ring B, J B , n, J D , J, o, X, R C and R A are as described herein.
Abstract translation: 本专利申请公开了至少下述式I或式Ib的化合物或其药学上可接受的盐，其中环B，JB，n，JD，J，o，X，RC和RA如本文所述。
-
7.发明申请2 - BENZYL, 3 - (PYRIMIDIN- 2 -YL) SUBSTITUTED PYRAZOLES USEFUL AS SGC STIMULATORS 审中-公开2 - 苄基，3-（吡咯烷-2-基）取代的吡唑可用作SGC刺激物
公开(公告)号：WO2013101830A1
公开(公告)日：2013-07-04
申请号：PCT/US2012/071654
申请日：2012-12-26
Applicant: IRONWOOD PHARMACEUTICALS, INC. , KIM, Charles , NAKAI, Takashi , MOORE, Joel , PERL, Nicholas, Robert , IM, G-yoon, Jamie , BARDEN, Timothy, Claude , IYENGAR, Rajesh, R. , ZIMMER, Daniel, P. , FRETZEN, Angelika , RENHOWE, Paul, Allan
Inventor： KIM, Charles , NAKAI, Takashi , MOORE, Joel , PERL, Nicholas, Robert , IM, G-yoon, Jamie , BARDEN, Timothy, Claude , IYENGAR, Rajesh, R. , ZIMMER, Daniel, P. , FRETZEN, Angelika , RENHOWE, Paul, Allan
IPC: C07D413/14 , C07D403/04 , C07D417/14 , A61K31/4155 , A61P43/00
CPC classification number: A61K31/52 , A61K31/4439 , A61K31/506 , A61K31/513 , A61K31/519 , A61K45/06 , C07D403/04 , C07D413/14 , C07D417/14 , C07D473/00 , C07D487/04 , C07D513/22
Abstract: 2-Benzyl, 3 - (pyrimidin- 2 -YL) substituted pyrazoles are described. They are useful as stimulators of sGC, particularly NO - independent, heme - dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed.
Abstract translation: 描述2-苄基，3-（嘧啶-2-基）取代的吡唑。 它们可用作sGC的刺激剂，特别是NO-不依赖于血红素依赖性刺激物。 这些化合物可用于治疗，预防或治疗本文公开的各种疾病。
-
公开(公告)号：WO2009126737A3
公开(公告)日：2010-01-14
申请号：PCT/US2009039954
申请日：2009-04-08
Applicant: SLOAN KETTERING INST CANCER , GIN DAVID , ADAMS MICHELLE , DENG KAI , PERL NICHOLAS , WON ANNIE , LIVINGSTON PHILIP , RAGUPATHI GOVIND
Inventor： GIN DAVID , ADAMS MICHELLE , DENG KAI , PERL NICHOLAS , WON ANNIE , LIVINGSTON PHILIP , RAGUPATHI GOVIND
IPC: C07H15/24 , A61K31/704 , A61P37/04
CPC classification number: C07H15/256 , A61K31/7024 , A61K31/704 , A61K39/385 , C07H13/08 , C07H15/24
Abstract: The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.
Abstract translation: 本发明涉及三萜糖苷皂苷衍生的佐剂，其合成，其中间体及其用途。 QS-7是一种有效的免疫佐剂，其毒性明显低于QS-21，这是一种相关的皂苷，目前是抗癌和抗病毒疫苗中有利的佐剂。 繁琐的分离和纯化方案阻碍了QS-7的临床发展。 提供了一种新的半合成方法，其中使用水解的前配皂素混合物合成QS-7，QS-21及相关类似物，极大地方便了QS-7和QS-21类似物的临床前和临床评估。
-
公开(公告)号：WO2016044446A3
公开(公告)日：2016-06-16
申请号：PCT/US2015050467
申请日：2015-09-16
Applicant: IRONWOOD PHARMACEUTICALS INC , RENNIE GLEN ROBERT , PERL NICHOLAS , MERMERIAN ARA , JUNG JOON , JIA JAMES , IYENGAR RAJESH R , IM G-YOON JAMIE , BARDEN TIMOTHY CLAUDE
Inventor： RENNIE GLEN ROBERT , PERL NICHOLAS , MERMERIAN ARA , JUNG JOON , JIA JAMES , IYENGAR RAJESH R , IM G-YOON JAMIE , BARDEN TIMOTHY CLAUDE , SHEPPECK JAMES EDWARD , RENHOWE PAUL ALLAN , NAKAI TAKASHI , LEE THOMAS WAI-HO , IYER KARTHIK
IPC: C07D401/14 , A61K31/4155 , A61P9/08 , A61P37/06 , C07D401/04 , C07D405/14 , C07D413/14 , C07D417/14
CPC classification number: C07D401/04 , C07D401/14 , C07D405/14 , C07D413/14 , C07D417/14
Abstract: The present patent application discloses at least the compounds according to Formula I' shown below, or pharmaceutically acceptable salts thereof, Formula (I) wherein ring D, ring A, ring E, JB, n, JD, J, X, Z, Z1, RC1, RC2, Y, R9, o and W are as defined herein.
Abstract translation: 本专利申请公开了至少如下所示的根据式I'的化合物或其药学上可接受的盐，其中环D，环A，环E，JB，n，JD，J，X，Z，Z 1 ，RC1，RC2，Y，R9，o和W如本文所定义。
-
公开(公告)号：WO2009126737A2
公开(公告)日：2009-10-15
申请号：PCT/US2009/039954
申请日：2009-04-08
Applicant: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , GIN, David , ADAMS, Michelle , DENG, Kai , PERL, Nicholas , WON, Annie , LIVINGSTON, Philip , RAGUPATHI, Govind
Inventor： GIN, David , ADAMS, Michelle , DENG, Kai , PERL, Nicholas , WON, Annie , LIVINGSTON, Philip , RAGUPATHI, Govind
IPC: C07H15/24 , A61K31/704 , A61P37/04
CPC classification number: C07H15/256 , A61K31/7024 , A61K31/704 , A61K39/385 , C07H13/08 , C07H15/24
Abstract: The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.
Abstract translation: 本发明涉及三萜糖苷皂苷衍生的佐剂，其合成，其中间体及其用途。 QS-7是一种有效的免疫佐剂，其毒性明显低于QS-21，该蛋白是目前抗癌和抗病毒疫苗中有利的佐剂的相关皂苷。 繁琐的分离和纯化方案阻碍了QS-7的临床发展。 提供了一种新的半合成方法，其中使用水解的前配皂素混合物合成QS-7，QS-21及相关类似物，极大地方便了QS-7和QS-21类似物的临床前和临床评估。
-
-
-
-
-
-
-
-
-
Search Results
18
records
(took 0.024 seconds)
